News + Events2019-02-14T10:49:18+00:00

Latest Press Releases

Cadent Therapeutics Announces FDA acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)

January 23rd, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883...

Load More Posts